RYTM vs. VTRS, RDY, ASND, SRPT, PCVX, QGEN, ROIV, RVMD, LNTH, and LEGN
Should you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.
Rhythm Pharmaceuticals vs.
Rhythm Pharmaceuticals (NASDAQ:RYTM) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability.
Rhythm Pharmaceuticals presently has a consensus price target of $69.46, suggesting a potential upside of 29.30%. Viatris has a consensus price target of $10.50, suggesting a potential upside of 12.90%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Rhythm Pharmaceuticals is more favorable than Viatris.
Rhythm Pharmaceuticals received 281 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 67.71% of users gave Rhythm Pharmaceuticals an outperform vote while only 34.85% of users gave Viatris an outperform vote.
Viatris has higher revenue and earnings than Rhythm Pharmaceuticals. Viatris is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
79.9% of Viatris shares are owned by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Rhythm Pharmaceuticals had 9 more articles in the media than Viatris. MarketBeat recorded 22 mentions for Rhythm Pharmaceuticals and 13 mentions for Viatris. Rhythm Pharmaceuticals' average media sentiment score of 0.42 beat Viatris' score of -0.03 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.
Viatris has a net margin of -5.87% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Viatris' return on equity of 16.46% beat Rhythm Pharmaceuticals' return on equity.
Rhythm Pharmaceuticals has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500. Comparatively, Viatris has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
Summary
Rhythm Pharmaceuticals beats Viatris on 11 of the 18 factors compared between the two stocks.
Get Rhythm Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rhythm Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RYTM) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy RYTM Stock Free RYTM Stock Alerts